Pilot study of psilocybin in patients with post-treatment lyme disease
Scientific Reports February 25, 2026 Albert Garcia‐romeu, Gideon P. Naudé, Alison W. Rebman et al. 2 citations
An estimated 10–20% of Lyme disease patients develop post-treatment Lyme disease (PTLD), a chronic syndrome with no established treatments. In an open-label pilot study of 20 participants with PTLD, two sessions of psilocybin (15 mg then 15 or 25 mg) with psychological support led to significant improvements in symptom burden and quality of life from enrollment through one month after the second dose, with benefits sustained at six months. At six months, general PTLD symptom burden decreased 40% from baseline, and mental and physical quality-of-life scores improved 13%. Mood, fatigue, sleep, and pain also improved. No serious adverse events occurred; common side effects were transient hypertension, headache, and tachycardia. The findings suggest psilocybin-assisted treatment is feasible and well-tolerated, warranting further research.